perinatology.com
OBPharm


Home > Reference  > OBPharm-Public

THE INFORMATION IN THE OBPHARMTM IS INTENDED SOLELY FOR USE BY THE MEDICAL PROFESSION. IT IS NOT INTENDED FOR LAY PERSONS.

FOCUS INFORMATION TECHNOLOGY, INC. DOES NOT ASSUME ANY RESPONSIBILITY FOR ANY ASPECT OF HEALTHCARE ADMINISTERED WITH THE AID OF THIS CONTENT. THE PRESCRIBING PHYSICIAN MUST BE FAMILIAR WITH THE FULL PRODUCT LABELING AS PROVIDED BY THE MANUFACTURER AND RELEVANT MEDICAL LITERATURE PRIOR TO USING THE OBPHARMTM .

Focus Information Technology makes no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the OBPharmTM . Please review the Disclaimer  before using this site.

The information provided on this site is updated periodically. It is likely that the information presented will not include all information currently available. Keep in mind the limitations of this information.


The Food and Drug Administration (FDA) created the following rating system in 1979 to categorize the potential risk to the fetus for a given drug.

Category A: Controlled human studies have demonstrated no fetal risk

Category B: Animal studies indicate no fetal risk, but no human studies, OR adverse effects in animals , but not in well- controlled human studies

Category C: No adequate human or animal studies, OR adverse fetal effects in animal studies, but no available human data.

Category D: Evidence of fetal risk, but benefits outweigh risks.

Category X: Evidence of fetal risk. Risks outweigh any benefits.

The U.S. Food and Drug Administration (FDA) has recommended the elimination of the current pregnancy categories A, B, C, D, and X. Instead the FDA has proposed that the pregnancy and lactation subsections of labeling should include a summary, which summarizes the risks of the medicine to the developing baby (fetus) or breast-feeding infant, and a discussion of the data supporting that summary [1] .

Until this labeling change becomes common practice:

Suggestions for Prescribing Medication in Pregnant Women [2]


    When possible:
  • Use medication only if absolutely indicated.
  • Avoid initiating therapy during the first trimester.
  • Select a medication with a proven track record in human pregnancy.
  • Use a single-agent.
  • Use the lowest effective dose.
  • Discourage the use of over-the counter drugs that might interact with prescription medications.
   Modified from: Norwitz ER,Greenberg JA.Rev Obstet Gynec ol. 2009;2(3):135-6

     The following site contains referenced information and  useful summaries:


A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z



A


B


C


D


E


F


G


H


I

 


J


K


L


M

Macrobid
Macrodantin
Magnesium sulfate, Hypomagnesemia
Magnesium sulfate, Neuroprotection
Magnesium sulfate, Preeclampsia, Eclampsia
Magnesium sulfate, Severe asthma
Magnesium sulfate, Torsades de pointe
Methyldopa
Metformin
Methimazole
Methotrexate, ectopic pregnancy
Methyldopa, (Aldomet®)
Micronase® (Glyburide)
Montelukast (Singulair®)


N


O

Oseltamivir (Tamiflu®)


P


Papilloma Virus (Genital Warts)
Pelvic Inflammatory Disease (PID)
Perioperative steroids
Platelets, Platelets Pheresis
Pneumococcal   vaccine
Postpartum Hemorrhage Algorithm
Prednisolone
Prenatal prevention of virilization in a female fetus with congenital adrenal hyperplasia
Preterm Labor
Progesterone
Propranolol
Propylthiouracil
PTU


Q


R


S


T


U

 Ursodiol, ursodeoxycholic acid, (Actigall®)


V

Vaccines
Vaginal Yeast Infection
Valacyclovir
Venofer injection


W


X


Y


Z

Zafirlukast
Zanamivir (Relenza ®)

REFERENCE

1. Pregnancy & Lactation Labeling. U.S. Department of Health & Human Services 12/18/2009 .Accesssed 1/27/09
2. Norwitz ER, Greenberg JA.Antibiotics in pregnancy: are they safe? Rev Obstet Gynecol. 2009 Summer;2(3):135-6. PMID: 19826569

 

Home | About | Disclaimer | Privacy | Contact
Copyright © 2009 by Focus Information Technology.
All rights reserved